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Photodynamic therapy with benzoporphyrin derivative
monoacid ring A and red light (PDT-BPD) has been
used to treat human choroidal hemangiomas, and may
be useful for cutaneous vascular lesions. The potential
for PDT-BPD to inhibit selectively vascular tumor
growth was tested in a mouse angiosarcoma model, of
which the tumor growth mimics the proliferative phase
of hemangiomas.Vascular tumors arising after intrader-
mal injection of immortalized murine endothelial cells
were exposed to 50 to 150 J per cm2 of 690 nm laser light
15 min after intravenous injection of 1 mg per kg BPD.
Tumor volume and gross response were followed after
PDT-BPD and compared with control tumors receiv-
ing no treatment, light alone, or BPD alone. At 2 wk,
hematoxylin-eosin and terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick
end labeling stained tumor sections was performed.
There was a selective, £uence-dependent inhibition of
tumor growth after PDT-BPD (pr0.05), typically with
eradication of tumors exposed to higher £uences. A
common e¡ect was the replacement of tumor by small
scar. Surrounding PDT-BPD exposed normal skin
showed no changes. Based on these results, we conclude
that PDT-BPD can lead to selective eradication of these
tumors. Further studies investigating the e⁄cacy of
PDT-BPD for human hemangiomas are warranted.
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P
hotodynamic therapy (PDT) employs a photosensitiz-
ing drug activated by light exposure after distribution
into tissue. Biodistribution of the drug in the tissue
largely determines what cells or structures are targeted
by PDT. Red light is often used in PDT to maximize
depth of penetration, which is usually less than 1 cm. Typically,
PDT causes potent local tissue e¡ects via the production of reac-
tive oxygen species and free radicals (Kalka et al, 2000).
Benzoporphyrin derivative monoacid ring A (BPD-MA) is a
second generation porphyrin photosensitizer that has a rapid up-
take, fast clearance, and is selectively taken up by endothelial cells
(Scott and Goa, 2000). BPD-MA shows signi¢cantly less adverse
reactions of skin photosensitivity, usually within 48 to 72 h. In
contrast, other photosensitizers such as por¢rmer sodium has a 6
to 8 wk photosensitivity duration, and other hematoporphyrin
compounds also may exhibit reactions for as late as 2 wk (Razum
et al, 1987). PDT with BPD-MA (PDT-BPD) has been success-
fully used for the treatment of cancer, which is partly due to de-
struction of the vasculature (Kurohane et al, 2001). Furthermore,
this modality has been reported for treatment of vascular disor-
ders such as choroidal hemangiomas (Schmidt-Erfurth et al, 1998;
Madreperla, 2001) and classic subfoveal choroidal neovasculariza-
tion in age-related macular degeneration. Experimental evidence
suggests that occlusion of abnormal vessels is the principal me-
chanism of action of PDT-BPD resulting in necrosis and ¢brosis
of the vascular tissue and secondary tumor regression (Schmidt-
Erfurth et al, 1994). Port-wine stains, which are nonproliferating
microvascular skin malformations, have been treated with a mix-
ture of porphyrins (Lin et al, 1997) and with hematoporphyrin
derivative (Jiang et al, 1998; Ouyang et al, 1998) in combination
with lasers with clinically satisfactory results.
To our knowledge no human cutaneous proliferative vascular
tumors have as yet been subjected to PDT-BPD. Hence, we
decided to investigate a possible role for this modality in the
treatment of juvenile hemangiomas, a very common and distinct
tumor of infancy. Current treatments often exhibit side-e¡ects
and have a variable response. Therefore, new modalities are
needed to treat these dis¢guring and occasionally life-threatening
vascular skin tumors.
This study was aimed at determining the possible applicability
of PDT-BPD to the treatment of vascular tumors while enhan-
cing our understanding of vascular phototoxicity as determined
by histologic evaluation. Because of the absence of an appropriate
hemangioma animal model, we decided to perform a preliminary
study using an angiosarcoma model in mice, which has some fea-
tures in common with cutaneous juvenile hemangiomas. We
found that PDT with BPD-MA results in selective tumor de-
struction and that tumor regression followed a £uence-dependent
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response. It appears that the therapeutic outcome is predomi-
nantly due to necrosis of vascular tumor tissue rather than to the
induction of apoptosis.
MATERIALS AND METHODS
Cell culture Immortalized murine endothelial MS1VEGF cells (ATCC,
CRL-2460, Manassas, Virginia) were obtained and were maintained in a
humidi¢ed 5% CO2 atmosphere at 371C using Dulbecco’s modi¢ed Eagle
medium (ATCC) supplemented with 10% fetal bovine serum (Mediatech
Inc, Herndon, Virginia) and 1% penicillin^streptomycin (Mediatech Inc).
Upon reaching con£uence, cells were trypsinized with 0.25% trypsin^
ethylenediamine tetraacetic acid (Sigma, St Louis, Missouri), passed and
subcultured up to 1:6. Cells from passages 5 to 15 were used to create the
animal model.
Animals Animal protocols were approved by the Internal Review
Board and met all guidelines of the Massachusetts General Hospital Use
and Care of Animals policy. Six week old male nude mice (Charles River
Laboratories,Wilmington, MA) were used for all experiments. Anesthesia
was performed by intraperitoneal injection with 0.5 mL of a mixture of
0.75 mL ketamine 50 mg per mL (Bedford Laboratories, Bedford, Ohio)
and 0.15 mL xylazine 100 mg per mL (Lloyd Laboratories, Shenandoah,
Iowa). Anesthetized animals received an intradermal injection of 2.5106
MS1 VEGF cells suspended in Dulbecco’s phosphate-bu¡ered saline
(Mediatech) in both hind legs using a 27 gauge needle (Sherwood
Medical, St Louis, Missouri). After each injection a de¢nite papule was
observed at the site, evidence of a successful intradermal injection.Within
2 wk the MS1VEGF cells gave rise to clearly visible angiosarcomas.
Photosensitizer Liposomal BPD-MA (Quadra LogicTechnologies, Inc.,
Vancouver, British Columbia, Canada) was stored in the dark at 41C.
BPD-MA was diluted in bu¡ered saline and the concentration was
calculated via measurement of the peak absorption at 688 nm using a
spectrophotometer (Hewlett-Packard, Model 8453, Palo Alto, California).
The diluted BPD-MA was likewise stored in the dark at 41C and was
always used within 72 h of its preparation.
Light source Light at a wavelength of 690 nm was delivered by a diode
laser (BWF series 690 nm diode laser, B & W TEK Inc., Newark,
Delaware). This diode laser system can provide up to 1 W of continuous,
690 nm wavelength red light delivered by an optical ¢ber. Prior to each
experiment the irradiance was assessed using a power meter (model 10A-
P-110, Ophir Optronic Inc., Danvers, Massachusetts). Irradiance was set
constantly at 100 mW per cm2, which showed no signi¢cant heat
production in tumors as monitored with a surface thermometer (model
HH23, microprocessor thermometer, K-type thermocouple, Omega
Engineering Inc., Stamford, Connecticut). This irradiance is less than that
of natural sunlight.
Experimental protocol and PDT delivery Exposure to laser light
occurred 10 to 14 d after injection of MS1 VEGF cells when tumors were
clearly visible. A total number of 43 tumors were randomly divided in
eight groups. Animals were anesthetized during each procedure as
mentioned above. Tumor size was determined by measuring the longest
and shortest diameters of the tumor with a digital caliper (Control
Company, Friendswood, Texas), and an estimate of the tumor volume
before treatment was calculated by multiplying the size of the longest axis
with the square of the shortest axis (long short2) (Arbiser et al, 1997).
Each lesion was photographed. In groups 1 to 4, animals received BPD-
MA intravenously at a dose of 1 mg per kg bodyweight via the retro-
orbital route using a 30 gauge needle (Becton Dickinson and Co.,
Franklin Lakes, New Jersey). The tumors in group 1 (n¼ 6), group 2
(n¼ 7), group 3 (n¼ 3), and group 4 (n¼ 6) were exposed to 50, 100, 125,
and 150 J per cm2 of laser light, respectively, 15 min after BPD-MA
administration. Animals in group 5 (n¼ 7) also received 1 mg BPD-MA
per kg, but the tumors were not exposed to laser. Tumors in group 6
(n¼ 4) and 7 (n¼ 4) were exposed to only laser without BPD-MA,
whereas those in group 8 (n¼ 6) were not exposed to any treatment at
all. The exposed spot size had a diameter of 1.1 cm, which allowed a 2 to
5 mm rim of normal skin around the tumor to be irradiated. The
remaining skin of the animals treated with laser with or without BPD-
MAwas covered with aluminum foil.
Evaluation of tumor responses Gross evaluation, tumor size and
volume, calculations of the percentage of tumor volume change, and
histologic analysis of excised tumors were performed to evaluate
treatment e⁄cacy. All tumors, treated and control, were observed
immediately after treatment, 24 h later and then every other day until the
animals were euthanized. Features evaluated included the presence of color
change, ulceration, erythema, edema, crusting, and scarring. All animals
were euthanized 12 to 15 d after the time of treatment. Remaining tumor
volume was assessed as described before and changes in estimated tumor
volume were calculated as a percentage of original volume before any
treatment. This allowed comparison of treatment e⁄cacy between tumors
regardless of di¡erences in original tumor volume. Photography was also
performed at the time of euthanasia. Tumor or other tissue at the site of
treatment, for example scars or crusts, were excised by a simple excision
and were ¢xed in 4% neutral bu¡ered formalin at least overnight. Fixed
specimens were routinely processed according to standard methodology,
embedded in para⁄n, and cut in 5 mm sections.
Hematoxylin and eosin stained sections were analyzed in blinded
fashion by two investigators (I.S.C. and M.C.M.) with an Olympus BX40
microscope. Any disagreements were resolved by consensus consultation.
Microscopic evaluation included the use of a scoring system established
prior to the evaluation to insure concordance. The presence of viable
tumor, thrombi, architectural disruption, viable follicles, and ¢brosis or
scarring of the dermis or tumor were scored using a scale from 1 up to 4.
The presence of in£ammation and ulceration and/or crusting was graded as
being present or not.
Cells undergoing apoptosis were visualized by TUNEL labeling
(Terminal deoxynucleotidyl transferase-mediated deoxy Uridine triphosphate
Nick End Labeling) utilizing the ApopTag (Intergen Company, Norcross,
Georgia). Brie£y, the tissue specimens were depara⁄nized and then
pretreated with a protein digesting enzyme followed by endogenous
peroxidase quenching. A working strength TdT (terminal deoxynucleo-
tidyl transferase) enzyme was then applied to the specimen followed by
application of anti-digoxigenin conjugate. Color was developed in
peroxidase substrate and after appropriate washing a counterstain with
0.5% methyl green was applied. After appropriate dehydration the
specimens were mounted and covered with a glass coverslip and viewed
with the light microscope. All sections were also analyzed in a blinded
fashion. The presence of apoptotic nuclei in tumor, scar tissue, thrombi,
and ¢brotic tissue around the tumor was scored on a scale from 1 to 4
based upon the apparent fraction of the nuclei that stained positively.
Statistical analysis Fluence dependency was assessed by comparing
tumor volumes after PDT-BPD using 50, 100, 125, and 150 J per cm2 with
the volume of tumors treated with only BPD-MA (control). The eight
groups were also divided into three categories: category A received PDT-
BPD (groups 1^4), category B received either BPD-MA alone or laser light
alone (groups 5^7), and category C received no treatment (group 8).
Analyses were performed to compare the di¡erences between these three
categories. Analyses were performed using Mann^Whitney and least
signi¢cant di¡erence tests. The hematoxylin and eosin and TUNEL
histopathology scores were compared using Chi-square and Kruskal^
Wallis tests. po0.05 was considered statistically signi¢cant.
RESULTS
Gross evaluation showed a clear £uence-dependent
di¡erence between treated and control tumors Immediately
after treatment, tumors receiving PDT with 100 J per cm2 or
higher showed in some cases (36%) mild whitening or
blanching of the tumor. This change was never observed in
tumors that received PDT with 50 J per cm2, nor in control
groups (category B and C). In the follow-up period there was a
clear di¡erence in the reaction of PDT-treated tumors compared
with tumors in the control groups (Fig 1, columns I and II).
PDT-treated tumors showed a variety of changes that were
£uence related. Most tumors (80%) developed edema with the
reaction extending to some degree into the surrounding tissue
within 24 h. Subsequently, most tumors (91%) developed a
dusky black discoloration, in 67% preceded by purpura, grossly
consistent with tumor necrosis. Within 4 to 6 d the dusky area
developed a crust, which resulted in a scar by 12 to 15 d. The
changes in tumors treated with lower £uences were of milder
degree with the development of hemorrhage, with less crusting
and scarring and with persistence of tumor in some cases. Higher
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£uences consistently resulted in striking crust formation and
scarring with virtual gross disappearance of the tumor. None of
the control tumors in categories B and C showed any of the
above-mentioned reactions; they all continued to increase in
size.
The speci¢city of PDT for the tumor tissue relative to
surrounding skin also exposed to PDT was evident. Besides
some edema in the immediate adjacent peritumoral skin, no
other gross evidence of phototoxicity was noted. The rest of the
normal skin of the animals did not show any evidence of
phototoxicity during follow-up.
Tumor volume of PDT-BPD treated tumors was signi¢-
cantly reduced in a £uence dependent way Percentage of
tumor volume change was statistically signi¢cantly di¡erent in
treated tumors compared with controls. Tumors treated with the
combination of BPD-MA and laser (categoryA) showed a mean
decrease of 65% in tumor volume after treatment, whereas
tumors receiving either BPD-MA alone or laser alone (category
B) showed an increase in tumor volume of 42% (A vs B:
po0.0001). Tumors receiving no treatment (category C) showed
an increase of 27% in volume (A vs C: po0.01). Comparison
of categories B and C showed no statistically signi¢cant
di¡erence.
Tumor volume reduction after PDT-BPD showed a £uence
dependency. Higher £uences resulted in a smaller tumor volume
(Fig 2), which was statistically signi¢cant for tumors receiving
100, 125, and 150 J per cm2 compared with control, i.e., tumors
receiving only BPD-MA and no laser (po0.05). Between the 50
J per cm2 and control groups no statistical signi¢cant di¡erence
was found.
Histologic examination revealed no changes among control
groups All excised control tumors (groups 5^8) showed a
tumor mass composed of proliferated vessels that formed highly
irregular spaces as the tumor dissected amidst the collagen ¢bers
(Fig 1g,h). The malignant cells were thrown into papillary folds
or tongues that jutted into the spaces ¢lled with red blood cells
and neutrophils. In all excised control tumors thrombi were
present and were found in two locations depending on the size
of the tumor. In smaller tumors the thrombi were located in the
periphery; in larger tumors thrombi were large and found
centrally often in zones of apparent spontaneous tumor necrosis.
All of these central zones were surrounded by viable tumor in
control specimens. The epidermis overlying the tumor was
normal. Intact follicles were present but were displaced by the
tumor nodule when large. In some of the larger tumors a
¢brous response was noted below the tumor mass.
Figure1. Clinical and histologic ¢ndings in a mouse model angiosarcoma.The pictures in column I show tumors grown 10 to 14 d after injection of
MS1VEGF cells. Column II shows pictures of tumors, 2 wk after treatment with increasing £uences. Columns III and IV show the morphologic changes of
the excised tumor tissue, 2 wk after treatment. Note the absence of signi¢cant destructive alterations in the control group (III g and IV h).The picture of the
control tumor is representative for all control tumors. Scale bar¼ 200 mm.
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Histologic examination permitted a clear distinction
between the control and the treated groups with £uences of
100 J per cm2 and higher After comparison of tumor samples
that received PDT-BPD (category A) with control tumors
(categories B and C, Fig 1, columns III and IV), it was clear that
there was less viable tumor remaining in tumors receiving PDT-
BPD in contrast to the control categories B and C (po0.0001).
This observation showed a £uence dependency, as there was
almost no di¡erence between control tumors and tumors treated
with 50 J per cm2. Thrombosis was a naturally occurring,
spontaneous phenomenon shown clearly by the presence of
more thrombi in untreated compared with treated groups
(Fig 1g,a). In contrast, PDT-BPD treated tumors showed a
signi¢cant amount of ¢brosis and destruction of the cutaneous
structures (po0.0001) and even the subjacent skeletal muscle in
some cases (Fig 1e,f). Subcutaneously located treated tumors did
not show any destruction of the overlying epidermis or dermis,
indicating selective tumor destruction (Fig 3).
Crusting and/or ulceration was a phenomenon that exclusively
occurred in PDT-BPD-treated tumors (po0.0001). Also related
to the treatment e¡ect was the presence of an in£ammatory
response. In all tumors of the control groups, scattered
neutrophils were often noted in the intravascular spaces and
were considered an intrinsic part of the tumor presentation. In
the treated groups, however, a prominent in£ammatory response
was observed compared with the control groups (p¼ 0.03) and
appeared £uence dependent (Fig 1b,d,f vs h). Around these
altered areas granulation tissue with increased numbers of
lymphocytes, other mononuclear cells and elongate bipolar cells,
were clearly evident. Destruction of hair follicles also appeared to
be £uence dependent in the PDT-BPD treated category. Fibrosis
was often present in both control and PDT-BPD-treated
categories being apparently spontaneous and reactive to tumor
in the former, and reactive to tumor destruction in the latter,
also in a £uence-dependent manner. At the highest £uence of
150 J per cm2 there was full thickness destruction of the tumor
(Fig 1e,f).
At 2 wk follow-up, no striking histologic di¡erences were
found between control tumors and those treated with BPD
and 50 J per cm2 The epidermis, hair follicles, and tumor
showed no changes di¡erent from the control specimens except
for some central tumor focal ¢brous bands and a slight increase
in deep dermal ¢brosis and cellularity.
PDT-BPD with 100, 125, and 150 J per cm2 resulted in partial
to complete necrosis of the tumor in a £uence-dependent
manner In tumors treated with BPD and 100 J per cm2 a
striking full thickness ulcer extending even into the muscle layer
was observed. Necrotic tumor was noted amidst debris in the
ulcer (Fig 1d). Adjacent to the ulcer there was a striking
neutrophilic in¢ltrate palisading around areas of complete
tumor and muscle necrosis. At the base there was dense ¢brosis
with granulation tissue admixed with residual areas of viable
tumor, that was also observed especially at the periphery of the
ulcer bed. At the edge of the ulcer the epidermis and follicles
showed reactive hyperplasia.
In tumors treated with BPD and 125 J per cm2 a sharply
demarcated full thickness ulcer involving the epidermis, dermis,
fat, and muscle was covered by a large-scale crust. No viable
tumor was visible in this group. A neutrophil-rich granulation
tissue palisaded around the necrotic ulcer bed and was
interrupted by scattered skeletal muscle cells. Focal viable
epidermis and follicles, both with dyskeratotic cells were present
adjacent to the ulcer.
In tumors treated with BPD and 150 J per cm2, the ulcer and
extent of necrosis and in£ammation involving the tumor and the
overlying tissue was similar to the last two groups. No viable
tumor was noted. In addition, at the edge of the ulcer focal
epidermal necrosis, follicular necrosis, and skeletal muscle
necrosis was present (Fig 1f).
TUNEL histology In the control categories B and C less
positive staining by TUNEL method (apoptosis) was observed
than in the treated tumors of category A but without statistical
signi¢cance. In both control and treated categories, a ¢brosis,
apparently spontaneous and reactive to tumor in the former and
Figure 3.The skin overlying a tumor showing extensive destruction
by PDT-BPD is completely normal.This observation supports the se-
lectivity of PDT-BPD for the tumor.
Figure 2. Tumor volume reduction is £uence dependent. Bars repre-
sent tumor volumes before and after treatment with PDT-BPD, and error
bars represent SEM (n¼ 29). The £uence of 0 J per cm2 indicates unirra-
diated tumors, only treated with BPD-MA (1 mg per kg), thus serving as
control. Signi¢cant smaller volumes after treatment compared with the
volumes after treatment in the control group: *po0.05, **pp0.01. Statis-
tical analyses were performed using the Mann^Whitney test.
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reactive to tumor destruction in the latter, exhibited apoptosis.
In control tumors of categories B and C showing prominent
thrombosis, there was focal striking evidence of positive
staining. Areas of central tumor thrombosis were associated with
intense decoration of almost 100% of the nuclei with the
immunoperoxidase labeled antibody. De¢nite but less staining
was noted in the tumor immediately adjacent to the thrombosed
area. Likewise, staining was noted in the residual tumor adjacent
to necrotic treated areas. In the scars that resulted from the
successful elimination of virtually the entire tumor in the treated
category A, positive staining was likewise very prominently
recorded.
DISCUSSION
This study shows that PDTwith BPD-MA is capable of causing
e¡ective, £uence-dependent, selective necrosis of proliferative
vascular tumors of the skin in this nude mouse angiosarcoma
model. PDT-BPD-treated tumors were easily distinguished from
controls by their gross appearance after treatment. Control tu-
mors did not show any changes, whereas treated tumors devel-
oped changes such as edema, discoloration, focal ulceration, and
crusting with subsequent signi¢cant regression (po0.01) and scar
formation.These changes were con¢rmed by histologic examina-
tion that showed good correlation with the gross morphology.
We choose the nude mouse angiosarcoma model, because it is a
relatively slow-growing tumor with some histopathologic fea-
tures similar to juvenile hemangiomas (Arbiser et al, 2000). In ad-
dition, the growth pattern of these angiosarcomas resembles that
of hemangiomas in the proliferative phase, i.e., a well-de¢ned
vascular tumor in the dermis and subcutis. Juvenile hemangiomas
are a common tumor of infancy. Although these tumors are his-
tologically benign and exhibit spontaneous involution, some-
times they result in functional complications (Drolet et al, 1999)
and a signi¢cant number of children are left after regression with
residual skin changes, such as scarring or atrophy (Metry and He-
bert, 2000). Response to treatment with systemic steroids, pulse-
dye laser, and surgery is variable and is often associated with side-
e¡ects (Williams et al, 2000). The need for alternative treatment
modalities is considerable.
BPD-MA (Vertepor¢n) is a potent, second generation photo-
sensitizing agent, which is systemically administered in an aqu-
eous solution. It is activated at a wavelength of 692 nm that
penetrates deeply into the skin and has low attenuation by hemo-
globin. Furthermore, BPD-MA demonstrates signi¢cantly less
phototoxicity in normal skin when compared with other hema-
toporphyrin derivatives. Skin phototoxicity depends on the drug
concentration in tissue and especially on the plasma levels (Lin
et al, 1998). Tissue selectivity depends on the time between light
exposure and BPD-MA intravenous injection.When light is gi-
ven early after intravenous injection, BPD-MA has shown high
selectivity for the vascular compartment (Gonzalez et al, 2000).
With an excellent safety pro¢le, BPD-MA is already an FDA-
approved treatment for classic subfoveal choroidal neovasculariza-
tion in age-related macular degeneration and is currently in phase
I^II clinical trials for certain skin disorders such as skin cancer and
psoriasis. A report of the successful treatment of choroidal he-
mangiomas with PDT-BPD (Barbazetto and Schmidt-Erfurth,
2000), the results of this animal study, and the overall favorable
cosmetic results typical for PDT treatment of the skin suggest
that juvenile hemangiomas may be treatable with PDT-BPD;
however, the correlation between response of this tumor model,
and response of human juvenile hemangiomas to PDT-BPD is
unknown and warrants further studies.
Variables a¡ecting tumor response In general, tumor
response to PDT-BPD was related to both £uence and tumor
size. For example, only some small tumors treated with 50 J per
cm2 responded. Most tumors, except for one large tumor, treated
with 100 J per cm2 responded. All neoplasms treated at 125 J per
cm2 responded. It should be stressed that the mouse tumors in
this study were malignant, and, in general, angiosarcomas have a
high propensity for recurrence. Thus a tumor in this study group
treated at 150 J per cm2 recurred. Consequently, a more e¡ective
response may be expected in benign tumors, such as juvenile
hemangiomas. We did not study the in£uence of drug dose,
time between administration of BPD and light, light irradiance,
wavelength, or other factors. We chose a dose of 1 mg per kg
BPD-MA as previous experiments showed that this dose did not
lead to any general phototoxicity in normal animal skin.We also
kept the time of exposure to laser after BPD-MA administration
constant at 15 min, when BPD is known to be present in the
circulation (Richter et al, 1994).
Selectivity for tumors Normal skin surrounding the tumor
did not show the gross changes observed in tumor tissue after
PDT. Histologically, a tumor that received PDT-BPD showed
major changes, surrounded by adjacent una¡ected skin. Fur-
thermore, subcutaneously located treated tumors that strikingly
responded to therapy did not show any destruction of the
overlying epidermis (Fig 3). These observations con¢rm the sele-
ctivity of PDT-BPD for tumor tissue over a large £uence range.
We hypothesize that the ulceration of the epidermis and necrosis
of the dermis and follicles occurring in association with high
£uences was due to secondary ischemic necrosis associated with
the massive tumor necrosis. The typical ¢nal appearance of skin
after necrosis, crust formation, and tumor regression was a
variably sized scar surrounded by normal skin. Scarring as a
result of this therapy in humans would be a serious drawback, as
it represents one of the most undesirable sequelae of involution
and current therapy of this lesions. Hence, a carefully monitored
human study must be undertaken, including the use of di¡erent
£uences to see if scarring with PDT-BPD therapy can be avoided.
Mechanisms of tumor response Whereas the study of
apoptosis by the TUNEL method did not lead to statistically
signi¢cant results, there were trends subject to interpretation. In
both control and treated groups a zonal pattern of apoptosis
was noted in the viable tumors, immediately adjacent to the
thrombotic and necrotic areas, respectively. This observation
suggests a possible role for apoptosis in the tumor response to
therapy or spontaneous thrombosis. Further studies in the ¢rst few
days after treatment should be carried out to con¢rm any early role
of apoptosis. Another observation of TUNEL staining in the
reactive spontaneous scars of control tumors and those reactive to
therapy suggests that apoptosis remodeling occurs in these ¢brous
reactions. The evaluation of hematoxylin and eosin stained sections
supports the interpretations from theTUNEL method.
In summary, our results indicate the e⁄cacy and speci¢city of
PDTusing BPD-MA and red light in the treatment of cutaneous
proliferative vascular tumors in an angiosarcoma nude mouse
model. The ¢ndings of this study support a properly designed trial
of PDTwith BPD-MA for juvenile hemangiomas in humans.
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